Asembia: WellDyne Leaders Highlight Precision Medicine

Asembia’s Specialty Pharmacy Summit is described as the event “where all of specialty pharmacy meets,” a gathering of 5,000+ industry attendees featuring educational sessions, continuing education programs and networking opportunities. At this year’s conference, two WellDyne leaders – David Skomo, Chief Operating Officer and Nick Page, Chief Clinical Officer – will lead participants into the future with insights into The New Generation of Precision Medicine.

Rapid advancement in precision medicine is good news for patients with complex, chronic conditions, and for plan sponsors. Is this patient a slow or fast metabolizer? What is the most effective drug to treat the patient’s condition? Should a physician-recommended therapy escalation receive a closer look? Guided by the patient’s DNA, the answers become more clear.

“Through pharmacogenomic testing and the targeted approach of precision medicine, we can predict how a patient will metabolize and respond to a specific drug,” Nick explains. “Prescribers can make the best choice of drug and dosage for each individual – the first time, minimizing side effects and costly trial-and-error.”

Long used successfully in the identification and treatment of cancer, pharmacogenomic testing is rapidly expanding in other areas such as diabetes and inflammatory conditions. “Moving into the future of precision medicine, PBMs will play a lead role in harnessing new approaches for improved health outcomes and efficient use of new medicines,” adds Dave. “PBMs staying ahead of these rapid advancements in testing, technology and treatment will educate and influence prescribers and patients, interpret test results and identify therapeutic opportunities for improved patient care.”

With a 33% projected investment increase in precision medicine from pharmaceutical leaders during the next five years, this area is primed for rapid growth. The session at Asembia will explore how pharmacists and PBMs play a pivotal role in the application of genetic testing now and into the future.